ZymoGenetics

Last updated
ZymoGenetics
Company typePublic
IndustryBiotechnology/Pharmaceuticals
Founded1981;43 years ago (1981) in Seattle, Washington
FoundersEarl W. Davie, Michael Smith and Benjamin D. Hall
HeadquartersLake Union Steam Plant Building,
1201 Eastlake Avenue East, Seattle
,
Washington, USA
Key people
Stephanie Feldt
ProductsPharmaceuticals
Owner Bristol-Myers Squibb
Website Archived website

ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA, [1] based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East. [2] It was closed in 2019 after its acquisition by Bristol Myers Squibb. [3] [4]

Contents

The company was founded in 1981 [5] by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia. [2] Initially named Zymos, [6] the company was forced to change its name to ZymoGenetics under threat of trademark infringement from the similarly named semiconductor company ZyMOS. [7] Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988. [8] It was spun off as a public company in 2000. [1] Bristol-Myers Squibb acquired the company in 2010 for $885 million. [9] [10]

ZymoGenetics' headquarters was previously in the landmark Lake Union Steam Plant building. [11] This structure was built from 1914 to 1921 by Seattle City Light, the municipal electric utility. [12] At the time, the building was in poor condition with many broken windows; Bruce Carter, the chief executive at the time, described it as "the mother of all fixer-uppers". [13] In December 2016, ZymoGenetics announced that they would not renew the lease to the Steam Plant building, due to expire in 2019; [14] the Fred Hutchinson Cancer Research Center later moved into it. [15] At the time, ZymoGenetics did not plan on closing its Bothell manufacturing site; [14] however, it was sold to Seattle Genetics in August 2017. [16] ZymoGenetics closed completely in 2019. [3] [4]

Corporate governance

In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals. [17]

Related Research Articles

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

<span class="mw-page-title-main">Fred Hutchinson Cancer Center</span> Cancer research institute in Seattle, US

The Fred Hutchinson Cancer Center, formerly known as the Fred Hutchinson Cancer Research Center and also known as Fred Hutch or The Hutch, is a cancer research institute established in 1975 in Seattle, Washington.

<span class="mw-page-title-main">Excedrin (brand)</span> Over-the-counter headache pain reliever

Excedrin is an over-the-counter headache pain reliever, typically in the form of tablets or caplets. It contains paracetamol (acetaminophen), aspirin, and caffeine. It was manufactured by Bristol-Myers Squibb until it was purchased by Novartis in July 2005 along with other products from BMS's over-the-counter business. As of March 2015, GSK holds majority ownership of Excedrin through a joint venture transaction with Novartis. On 18 July 2022, GSK spun off its consumer healthcare business to Haleon.

<span class="mw-page-title-main">Exelixis</span> American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

Medarex was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

Kosan Biosciences, Inc., was a pharmaceutical company which dealt with cancer therapeutics medications. The company was working on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.

<span class="mw-page-title-main">Apixaban</span> Anticoagulant medication

Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth.

<span class="mw-page-title-main">Jeremy Levin</span> American businessman

Jeremy Levin is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.

<span class="mw-page-title-main">Nivolumab</span> Cancer drug

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein.

Lamberto Andreotti is an Italian businessman. He is currently executive chairman of the board of Bristol Myers Squibb.

<span class="mw-page-title-main">BMS-906024</span> Chemical compound

BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia. The drug works as a pan-Notch inhibitor. The structure is one of a set patented in 2012, and is being studied in clinical trials.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

<span class="mw-page-title-main">Juno Therapeutics</span> American biopharmaceutical company

Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

Earl Warren Davie was an American biochemist. He was a professor emeritus of biochemistry at the University of Washington. Davie studied the blood proteins involved in coagulation and was among the first scientists to describe the steps of the clotting process. He was a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences.

<span class="mw-page-title-main">Fred Ramsdell</span>

Frederick J. "Fred" Ramsdell is an American immunologist. Ramsdell graduated from the University of California, San Diego in 1983 with a bachelor's degree in biology and from the University of California, Los Angeles in 1987 with a Ph.D. in immunology. As a postdoc he worked at the National Institutes of Health and subsequently in biotech companies in the Seattle area. He has served as a senior executive at several biotech companies Darwin Molecular/Celltech, ZymoGenetics, Novo Nordisk, and aTyr Pharma. Since the beginning of 2016, he has been Research Director at the Parker Institute for Cancer Immunotherapy in San Francisco.

IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.

References

  1. 1 2 Pollack, Andrew (23 October 2000). "ZymoGenetics Will Become Independent of Novo Nordisk". The New York Times . Archived from the original on May 18, 2020. Retrieved 21 May 2015. ZymoGenetics Inc. said it had arranged for $150 million in private financing that would allow it to become independent of its parent company, Novo Nordisk A.S. of Denmark.
  2. 1 2 "ZymoGenetics, a Bristol-Myers Squibb Company". Bristol-Myers Squibb. Archived from the original on March 22, 2017. Retrieved 21 May 2015.
  3. 1 2 McGrane, Clare (November 1, 2018). "Bristol-Myers Squibb will close its Seattle Zymogenetics operations next year". GeekWire. Archived from the original on May 18, 2020.
  4. 1 2 Romano, Benjamin (November 1, 2018). "Seattle biotech stalwart ZymoGenetics prepares for year-end closure". The Seattle Times . Archived from the original on May 18, 2020.
  5. ↑ Timmerman, Luke (25 January 2011). "Bristol-Myers Squibb to Stay in Seattle, Keep ZymoGenetics Workers". Xconomy. Archived from the original on May 18, 2020. Retrieved 21 May 2015. ZymoGenetics, the venerable biotech founded in 1981.
  6. ↑ "In Remembrance: Dr. Benjamin D. Hall (1932-2019)". Washington Research Foundation. Retrieved 2023-08-13.
  7. ↑ Dr. Ben Hall - November 1, 2011 , retrieved 2023-09-13
  8. ↑ "Novo Nordisk completes divestment of ZymoGenetics, Inc". Bionity.com. 13 October 2010. Archived from the original on May 18, 2020. Retrieved 21 May 2015. Novo Nordisk has been a shareholder of ZymoGenetics since 1988 and at the time of the transaction, Novo Nordisk owned 22,143,320 shares, equalling close to 26% of the share capital.
  9. ↑ Carroll, John (8 September 2010). "BMS forges $885M deal to buy ZymoGenetics". FierceBiotech. Archived from the original on May 18, 2020. Retrieved 21 May 2015. Bristol-Myers Squibb has struck a deal to buy Seattle-based ZymoGenetics for $885 million.
  10. ↑ "Bristol-Myers Squibb buying ZymoGenetics". September 7, 2010. Archived from the original on May 18, 2020.
  11. ↑ "Focus: Seattle; Transforming a Rundown Lake Shoreline (Published 1993)". 1993-07-04. Retrieved 2023-08-13.
  12. ↑ Timmerman, Luke (13 September 2010). "What Will Happen to ZymoGenetics' Landmark Headquarters when Bristol Calls the Shots?". Xconomy. Archived from the original on May 18, 2020. Retrieved 21 May 2015.
  13. ↑ Romano, Benjamin (June 15, 2018). "The Hutch's 30-year journey to the Lake Union steam plant". The Seattle Times . Archived from the original on May 18, 2020.
  14. 1 2 Lerman, Rachel (December 14, 2016). "ZymoGenetics won't renew South Lake Union lease". The Seattle Times . Archived from the original on May 18, 2020.
  15. ↑ Romano, Benjamin (June 11, 2018). "Hutch cancer center will put labs in Seattle's historic Lake Union steam plant". The Seattle Times . Archived from the original on May 18, 2020.
  16. ↑ Erb, George (August 1, 2017). "Seattle Genetics buys biotech factory in Bothell". The Seattle Times . Archived from the original on May 18, 2020.
  17. ↑ Slatko, Joshua (December 2013). "BMS changes senior management team" (PDF). People on the Move: Biopharma. Med Ad News . Vol. 32, no. 12. p. 27. ISSN   1067-733X. Archived (PDF) from the original on May 18, 2020.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.